Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10929268 | 0.85 | TDP1 (0.46) | GPR3L3MBTL1PRNPRXFP1GRM6 | |
| SCHEMBL14178295 | 0.83 | ROCK1 (0.40) | ROCK1GPR3L3MBTL1PRNPRXFP1 | |
| SCHEMBL6257040 | 0.79 | ROCK1 (0.40) | ROCK1GPR3L3MBTL1PRNPRXFP1 | |
| SCHEMBL13477894 | 0.78 | ROCK1 (0.46) | ROCK1GPR3L3MBTL1ALDH1A1ATM | |
| SCHEMBL6076483 | 0.78 | ROCK1 (0.72) | ROCK1L3MBTL1 | |
| SCHEMBL13810540 | 0.78 | BCKDK (0.40) | ROCK1GRM6ALDH1A1ALOX5TDP1 | |
| SCHEMBL13522979 | 0.77 | ROCK1 (0.44) | ROCK1GPR3L3MBTL1PRNPRXFP1 | |
| SCHEMBL18002934 | 0.77 | BRD4 (0.43) | ROCK1PRNPRXFP1ALDH1A1TDP1 | |
| SCHEMBL6251935 | 0.77 | ROCK1 (0.39) | ROCK1GPR3L3MBTL1PRNPRXFP1 | |
| SCHEMBL16996824 | 0.77 | GRM6 (0.52) | GRM6ALDH1A1ALOX5LIMK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180214414-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2018-08-02 | — | — | US | disclosed |
| US-9895348-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170100371-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2017-04-13 | — | — | US | disclosed |
| US-9475791-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150291552-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-10-15 | — | — | US | disclosed |
| US-20100025661-A1 | Luminescent material and organic electroluminescent device using the same | JNC CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100025661-A1 | Luminescent material and organic electroluminescent device using the same | JNC CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2134683-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ROCK1 875/4885GPR3 2917/4885L3MBTL1 2670/4885 |
| US-20170100371-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, SHBG, ESRRB | ROCK1 2975/4885GPR3 1720/4885L3MBTL1 4834/4885 |
| US-20180214414-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, SHBG, ESRRB | ROCK1 2975/4885GPR3 1720/4885L3MBTL1 4834/4885 |
| US-20100025661-A1 | Luminescent material and organic electroluminescent device using the same | TRPV3, TRPC3, HVCN1 | ROCK1 2829/4885GPR3 376/4885L3MBTL1 307/4885 |
| US-20150291552-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, SHBG, ESRRB | ROCK1 2975/4885GPR3 1720/4885L3MBTL1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.